The expression of glutaredoxin is increased in the human cervix in term pregnancy and immediately post-partum, particularly after prostaglandin-induced delivery.
Identifieur interne : 001046 ( Main/Exploration ); précédent : 001045; suivant : 001047The expression of glutaredoxin is increased in the human cervix in term pregnancy and immediately post-partum, particularly after prostaglandin-induced delivery.
Auteurs : L. Sahlin [Suède] ; H. Wang ; Y. Stjernholm ; M. Lundberg ; G. Ekman ; A. Holmgren ; H. ErikssonSource :
- Molecular human reproduction [ 1360-9947 ] ; 2000.
Descripteurs français
- KwdFr :
- ARN messager (métabolisme), Abortifs stéroïdiens (administration et posologie), Abortifs stéroïdiens (pharmacologie), Accouchement (procédure) (MeSH), Accouchement provoqué (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Biosynthèse des protéines (MeSH), Col de l'utérus (anatomopathologie), Col de l'utérus (métabolisme), Dinoprostone (administration et posologie), Dinoprostone (pharmacologie), Expression des gènes (MeSH), Femelle (MeSH), Glutarédoxines (MeSH), Grossesse (MeSH), Humains (MeSH), Mifépristone (administration et posologie), Mifépristone (pharmacologie), Oxidoreductases (MeSH), Protéines (génétique), Travail obstétrical (métabolisme).
- MESH :
- administration et posologie : Abortifs stéroïdiens, Dinoprostone, Mifépristone.
- anatomopathologie : Col de l'utérus.
- génétique : Protéines.
- métabolisme : ARN messager, Col de l'utérus, Travail obstétrical.
- pharmacologie : Abortifs stéroïdiens, Dinoprostone, Mifépristone.
- Accouchement (procédure), Accouchement provoqué, Adulte, Adulte d'âge moyen, Biosynthèse des protéines, Expression des gènes, Femelle, Glutarédoxines, Grossesse, Humains, Oxidoreductases.
English descriptors
- KwdEn :
- Abortifacient Agents, Steroidal (administration & dosage), Abortifacient Agents, Steroidal (pharmacology), Adult (MeSH), Cervix Uteri (metabolism), Cervix Uteri (pathology), Delivery, Obstetric (MeSH), Dinoprostone (administration & dosage), Dinoprostone (pharmacology), Female (MeSH), Gene Expression (MeSH), Glutaredoxins (MeSH), Humans (MeSH), Labor, Induced (MeSH), Labor, Obstetric (metabolism), Middle Aged (MeSH), Mifepristone (administration & dosage), Mifepristone (pharmacology), Oxidoreductases (MeSH), Pregnancy (MeSH), Protein Biosynthesis (MeSH), Proteins (genetics), RNA, Messenger (metabolism).
- MESH :
- chemical , administration & dosage : Abortifacient Agents, Steroidal, Dinoprostone, Mifepristone.
- chemical , genetics : Proteins.
- chemical , metabolism : RNA, Messenger.
- chemical , pharmacology : Abortifacient Agents, Steroidal, Dinoprostone, Mifepristone.
- metabolism : Cervix Uteri, Labor, Obstetric.
- pathology : Cervix Uteri.
- Adult, Delivery, Obstetric, Female, Gene Expression, Glutaredoxins, Humans, Labor, Induced, Middle Aged, Oxidoreductases, Pregnancy, Protein Biosynthesis.
Abstract
Glutaredoxins are glutathione disulphide oxidoreductases catalysing disulphide reductions via a redox active disulphide. We have examined the presence of glutaredoxin in the human cervix, and its differential expression during cervical remodelling in term pregnancy and immediately post-partum as compared to the non-pregnant state. Cervical biopsies were obtained from 24 term-pregnant and 24 post-partal women, of which 10 were taken after spontaneous delivery, 10 after prostaglandin-induced delivery and four after mifepristone-induced delivery, all obtained within 15 min after delivery. Six non-pregnant women served as controls. The tissues were analysed for the glutaredoxin mRNA levels using a solution hybridization method. Glutaredoxin mRNA was expressed in the human cervix, the level increased > or =2-fold at term pregnancy and immediately post-partum. The level of cervical glutaredoxin mRNA from prostaglandin E(2)-treated women was 3-fold higher than after spontaneous ripening and delivery. Localization of glutaredoxin was visualized with immunohistochemistry in cervices from two post-partal women, and was compared to that of thioredoxin. We conclude that glutaredoxin may be involved in the regulation of cervical ripening in humans, particularly in the inflammatory reaction seen during this process. Glutaredoxin mRNA levels are up-regulated after prostaglandin treatment, which is effective and the most commonly used substance for cervical priming and induction of labour.
DOI: 10.1093/molehr/6.12.1147
PubMed: 11101698
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The expression of glutaredoxin is increased in the human cervix in term pregnancy and immediately post-partum, particularly after prostaglandin-induced delivery.</title><author><name sortKey="Sahlin, L" sort="Sahlin, L" uniqKey="Sahlin L" first="L" last="Sahlin">L. Sahlin</name><affiliation wicri:level="3"><nlm:affiliation>Division for Reproductive Endocrinology, Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm,Sweden. Lena.Sahlin@kbh.ki.se</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Division for Reproductive Endocrinology, Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Wang, H" sort="Wang, H" uniqKey="Wang H" first="H" last="Wang">H. Wang</name></author><author><name sortKey="Stjernholm, Y" sort="Stjernholm, Y" uniqKey="Stjernholm Y" first="Y" last="Stjernholm">Y. Stjernholm</name></author><author><name sortKey="Lundberg, M" sort="Lundberg, M" uniqKey="Lundberg M" first="M" last="Lundberg">M. Lundberg</name></author><author><name sortKey="Ekman, G" sort="Ekman, G" uniqKey="Ekman G" first="G" last="Ekman">G. Ekman</name></author><author><name sortKey="Holmgren, A" sort="Holmgren, A" uniqKey="Holmgren A" first="A" last="Holmgren">A. Holmgren</name></author><author><name sortKey="Eriksson, H" sort="Eriksson, H" uniqKey="Eriksson H" first="H" last="Eriksson">H. Eriksson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:11101698</idno><idno type="pmid">11101698</idno><idno type="doi">10.1093/molehr/6.12.1147</idno><idno type="wicri:Area/Main/Corpus">001052</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001052</idno><idno type="wicri:Area/Main/Curation">001052</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001052</idno><idno type="wicri:Area/Main/Exploration">001052</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The expression of glutaredoxin is increased in the human cervix in term pregnancy and immediately post-partum, particularly after prostaglandin-induced delivery.</title><author><name sortKey="Sahlin, L" sort="Sahlin, L" uniqKey="Sahlin L" first="L" last="Sahlin">L. Sahlin</name><affiliation wicri:level="3"><nlm:affiliation>Division for Reproductive Endocrinology, Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm,Sweden. Lena.Sahlin@kbh.ki.se</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Division for Reproductive Endocrinology, Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Wang, H" sort="Wang, H" uniqKey="Wang H" first="H" last="Wang">H. Wang</name></author><author><name sortKey="Stjernholm, Y" sort="Stjernholm, Y" uniqKey="Stjernholm Y" first="Y" last="Stjernholm">Y. Stjernholm</name></author><author><name sortKey="Lundberg, M" sort="Lundberg, M" uniqKey="Lundberg M" first="M" last="Lundberg">M. Lundberg</name></author><author><name sortKey="Ekman, G" sort="Ekman, G" uniqKey="Ekman G" first="G" last="Ekman">G. Ekman</name></author><author><name sortKey="Holmgren, A" sort="Holmgren, A" uniqKey="Holmgren A" first="A" last="Holmgren">A. Holmgren</name></author><author><name sortKey="Eriksson, H" sort="Eriksson, H" uniqKey="Eriksson H" first="H" last="Eriksson">H. Eriksson</name></author></analytic><series><title level="j">Molecular human reproduction</title><idno type="ISSN">1360-9947</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abortifacient Agents, Steroidal (administration & dosage)</term><term>Abortifacient Agents, Steroidal (pharmacology)</term><term>Adult (MeSH)</term><term>Cervix Uteri (metabolism)</term><term>Cervix Uteri (pathology)</term><term>Delivery, Obstetric (MeSH)</term><term>Dinoprostone (administration & dosage)</term><term>Dinoprostone (pharmacology)</term><term>Female (MeSH)</term><term>Gene Expression (MeSH)</term><term>Glutaredoxins (MeSH)</term><term>Humans (MeSH)</term><term>Labor, Induced (MeSH)</term><term>Labor, Obstetric (metabolism)</term><term>Middle Aged (MeSH)</term><term>Mifepristone (administration & dosage)</term><term>Mifepristone (pharmacology)</term><term>Oxidoreductases (MeSH)</term><term>Pregnancy (MeSH)</term><term>Protein Biosynthesis (MeSH)</term><term>Proteins (genetics)</term><term>RNA, Messenger (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (métabolisme)</term><term>Abortifs stéroïdiens (administration et posologie)</term><term>Abortifs stéroïdiens (pharmacologie)</term><term>Accouchement (procédure) (MeSH)</term><term>Accouchement provoqué (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Biosynthèse des protéines (MeSH)</term><term>Col de l'utérus (anatomopathologie)</term><term>Col de l'utérus (métabolisme)</term><term>Dinoprostone (administration et posologie)</term><term>Dinoprostone (pharmacologie)</term><term>Expression des gènes (MeSH)</term><term>Femelle (MeSH)</term><term>Glutarédoxines (MeSH)</term><term>Grossesse (MeSH)</term><term>Humains (MeSH)</term><term>Mifépristone (administration et posologie)</term><term>Mifépristone (pharmacologie)</term><term>Oxidoreductases (MeSH)</term><term>Protéines (génétique)</term><term>Travail obstétrical (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Abortifacient Agents, Steroidal</term><term>Dinoprostone</term><term>Mifepristone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>RNA, Messenger</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Abortifacient Agents, Steroidal</term><term>Dinoprostone</term><term>Mifepristone</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Abortifs stéroïdiens</term><term>Dinoprostone</term><term>Mifépristone</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Col de l'utérus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cervix Uteri</term><term>Labor, Obstetric</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN messager</term><term>Col de l'utérus</term><term>Travail obstétrical</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Cervix Uteri</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Abortifs stéroïdiens</term><term>Dinoprostone</term><term>Mifépristone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Delivery, Obstetric</term><term>Female</term><term>Gene Expression</term><term>Glutaredoxins</term><term>Humans</term><term>Labor, Induced</term><term>Middle Aged</term><term>Oxidoreductases</term><term>Pregnancy</term><term>Protein Biosynthesis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Accouchement (procédure)</term><term>Accouchement provoqué</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Biosynthèse des protéines</term><term>Expression des gènes</term><term>Femelle</term><term>Glutarédoxines</term><term>Grossesse</term><term>Humains</term><term>Oxidoreductases</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Glutaredoxins are glutathione disulphide oxidoreductases catalysing disulphide reductions via a redox active disulphide. We have examined the presence of glutaredoxin in the human cervix, and its differential expression during cervical remodelling in term pregnancy and immediately post-partum as compared to the non-pregnant state. Cervical biopsies were obtained from 24 term-pregnant and 24 post-partal women, of which 10 were taken after spontaneous delivery, 10 after prostaglandin-induced delivery and four after mifepristone-induced delivery, all obtained within 15 min after delivery. Six non-pregnant women served as controls. The tissues were analysed for the glutaredoxin mRNA levels using a solution hybridization method. Glutaredoxin mRNA was expressed in the human cervix, the level increased > or =2-fold at term pregnancy and immediately post-partum. The level of cervical glutaredoxin mRNA from prostaglandin E(2)-treated women was 3-fold higher than after spontaneous ripening and delivery. Localization of glutaredoxin was visualized with immunohistochemistry in cervices from two post-partal women, and was compared to that of thioredoxin. We conclude that glutaredoxin may be involved in the regulation of cervical ripening in humans, particularly in the inflammatory reaction seen during this process. Glutaredoxin mRNA levels are up-regulated after prostaglandin treatment, which is effective and the most commonly used substance for cervical priming and induction of labour.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11101698</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1360-9947</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2000</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Molecular human reproduction</Title><ISOAbbreviation>Mol Hum Reprod</ISOAbbreviation></Journal><ArticleTitle>The expression of glutaredoxin is increased in the human cervix in term pregnancy and immediately post-partum, particularly after prostaglandin-induced delivery.</ArticleTitle><Pagination><MedlinePgn>1147-53</MedlinePgn></Pagination><Abstract><AbstractText>Glutaredoxins are glutathione disulphide oxidoreductases catalysing disulphide reductions via a redox active disulphide. We have examined the presence of glutaredoxin in the human cervix, and its differential expression during cervical remodelling in term pregnancy and immediately post-partum as compared to the non-pregnant state. Cervical biopsies were obtained from 24 term-pregnant and 24 post-partal women, of which 10 were taken after spontaneous delivery, 10 after prostaglandin-induced delivery and four after mifepristone-induced delivery, all obtained within 15 min after delivery. Six non-pregnant women served as controls. The tissues were analysed for the glutaredoxin mRNA levels using a solution hybridization method. Glutaredoxin mRNA was expressed in the human cervix, the level increased > or =2-fold at term pregnancy and immediately post-partum. The level of cervical glutaredoxin mRNA from prostaglandin E(2)-treated women was 3-fold higher than after spontaneous ripening and delivery. Localization of glutaredoxin was visualized with immunohistochemistry in cervices from two post-partal women, and was compared to that of thioredoxin. We conclude that glutaredoxin may be involved in the regulation of cervical ripening in humans, particularly in the inflammatory reaction seen during this process. Glutaredoxin mRNA levels are up-regulated after prostaglandin treatment, which is effective and the most commonly used substance for cervical priming and induction of labour.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sahlin</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division for Reproductive Endocrinology, Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm,Sweden. Lena.Sahlin@kbh.ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Stjernholm</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lundberg</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ekman</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Holmgren</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Hum Reprod</MedlineTA><NlmUniqueID>9513710</NlmUniqueID><ISSNLinking>1360-9947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000021">Abortifacient Agents, Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054477">Glutaredoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>320T6RNW1F</RegistryNumber><NameOfSubstance UI="D015735">Mifepristone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.-</RegistryNumber><NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance></Chemical><Chemical><RegistryNumber>K7Q1JQR04M</RegistryNumber><NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000021" MajorTopicYN="N">Abortifacient Agents, Steroidal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002584" MajorTopicYN="N">Cervix Uteri</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036861" MajorTopicYN="N">Delivery, Obstetric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054477" MajorTopicYN="N">Glutaredoxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007751" MajorTopicYN="Y">Labor, Induced</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007743" MajorTopicYN="N">Labor, Obstetric</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015735" MajorTopicYN="N">Mifepristone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010088" MajorTopicYN="Y">Oxidoreductases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="Y">Protein Biosynthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>2</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>2</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11101698</ArticleId><ArticleId IdType="doi">10.1093/molehr/6.12.1147</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Suède</li></country><region><li>Svealand</li></region><settlement><li>Stockholm</li></settlement></list><tree><noCountry><name sortKey="Ekman, G" sort="Ekman, G" uniqKey="Ekman G" first="G" last="Ekman">G. Ekman</name><name sortKey="Eriksson, H" sort="Eriksson, H" uniqKey="Eriksson H" first="H" last="Eriksson">H. Eriksson</name><name sortKey="Holmgren, A" sort="Holmgren, A" uniqKey="Holmgren A" first="A" last="Holmgren">A. Holmgren</name><name sortKey="Lundberg, M" sort="Lundberg, M" uniqKey="Lundberg M" first="M" last="Lundberg">M. Lundberg</name><name sortKey="Stjernholm, Y" sort="Stjernholm, Y" uniqKey="Stjernholm Y" first="Y" last="Stjernholm">Y. Stjernholm</name><name sortKey="Wang, H" sort="Wang, H" uniqKey="Wang H" first="H" last="Wang">H. Wang</name></noCountry><country name="Suède"><region name="Svealand"><name sortKey="Sahlin, L" sort="Sahlin, L" uniqKey="Sahlin L" first="L" last="Sahlin">L. Sahlin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/GlutaredoxinV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001046 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001046 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= GlutaredoxinV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11101698
|texte= The expression of glutaredoxin is increased in the human cervix in term pregnancy and immediately post-partum, particularly after prostaglandin-induced delivery.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11101698" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GlutaredoxinV1
| This area was generated with Dilib version V0.6.37. |  |